The binding of FGF2 to FGFR can activate PI3K/AKT signaling and affect the cytotoxicity of chemotherapeutic drugs, ultimately influencing the sensitivity of tumor cells to chemotherapeutic drugs [20]. This evidence concerns the gene FGF2 and neoplasm.